The pharmaceutical industry heads into 2026 carrying strong M&A momentum, a surging Chinese deal landscape and continued buzz around obesity drugs and new modalities.
Deals involving Chinese pharma and biotech firms reached $92.2 billion in potential value through November 2025. That’s nearly double the $51.9 billion recorded in 2024, according to Mark Lansdell, Director, Asset and Portfolio Strategy Practice Lead at Evaluate
“I expect this trend of rising deal value to continue into…
